Astellas Pharma

Astellas to Build an Aseptic Drug Products Plant in Ireland

Japanese drugmaker Astellas Pharma plans to build an aseptic drug products facility in County Kerry, Ireland, creating an estimated 350 engineering, science, technology and other jobs. Construction is expected to begin next year and be completed in 2028. Astellas expects the investment costs to amount to €330 million.

News

Astellas Buys US Bioelectronics Startup

Japanese drugmaker Astellas Pharma has agreed to buy US bioelectronics startup Iota Biosciences. The move follows their R&D agreement signed in August 2019, under which the two firms worked together on activities associated with Iota’s ultrasonic-powered bioelectronic devices, also known as neural dust, in a number of indications.

News

White Knight Could Be Elusive For Genzyme

Top-Feature

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Aenova Holding GmbH

Mastering Modified Release: The Pellet-Based Approach

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Interview

Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

ISPE D/A/CH e.V.